Chugai Pharmaceutical（CUP0）株式概要中外製薬株式会社は、子会社とともに、国内外において医薬品の研究開発、製造、販売、輸入および輸出を行っています。 詳細CUP0 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長3/6過去の実績6/6財務の健全性6/6配当金4/6報酬当社が推定した公正価値より37.2%で取引されている 収益は年間12.17%増加すると予測されています 過去1年間で収益は19.2%増加しました リスク分析不安定な配当実績 すべてのリスクチェックを見るCUP0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW476,782 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA476,782 investors already sharing narrativesYour Fair Value€Current Price€17.8057.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02t2016201920222025202620282031Revenue JP¥1.9tEarnings JP¥684.1bAdvancedSet Fair ValueView all narrativesChugai Pharmaceutical Co., Ltd. 競合他社Merck KGaASymbol: XTRA:MRKMarket cap: €62.1bDermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.1bSartoriusSymbol: XTRA:SRT3Market cap: €13.8bSanofiSymbol: ENXTPA:SANMarket cap: €87.5b価格と性能株価の高値、安値、推移の概要Chugai Pharmaceutical過去の株価現在の株価JP¥17.8052週高値JP¥28.6052週安値JP¥16.40ベータ0.561ヶ月の変化-10.10%3ヶ月変化-11.88%1年変化-14.42%3年間の変化n/a5年間の変化n/aIPOからの変化-1.66%最新ニュースお知らせ • 2hChugai Pharmaceutical Files For Additional Indication Of Enspryng For Prevention Of Relapse In MOG Antibody-Associated Disease In JapanChugai Pharmaceutical Co., Ltd. filed a regulatory application with the Ministry of Health, Labour and Welfare for an additional indication of 'prevention of relapse in MOG antibody-associated disease' for Enspryng [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. Enspryng received forerunner designation in 2023 as a treatment for the disease. If approved, Enspryng would become the first treatment covered by health insurance in Japan for the disease. This filing is based on results from METEOROID, a global phase III clinical study in adults and adolescents (aged 12-17 years) with MOGAD. Development in Japan is conducted by Chugai, and Japanese patients have participated in this study. Enspryng, created by Chugai, is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, which was the first product developed by applying Chugai's proprietary recycling antibody technology. Recycling antibody technology received 'The Imperial Invention Prize,' the highest honor of the Fiscal Year 2026 National Commendation for Invention. Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in approximately 90 countries, including Japan, the United States, and Europe. A global phase III clinical study is currently ongoing in autoimmune encephalitis (AIE). In addition, the U.S. Food and Drug Administration (FDA) has accepted the filing for thyroid eye disease (TED) and granted priority review. MOG antibody-associated disease (myelin oligodendrocyte glycoprotein antibody-associated disease, MOGAD) is an autoimmune disease involving demyelination by which a pathogenic autoantibody, an anti-MOG antibody, binds to MOG, which is expressed on the surface of the myelin sheath in the central nervous system. MOGAD causes inflammation of the optic nerves, spinal cord and brain, with symptoms such as visual impairment, loss of sensation, motor dysfunction and dysuria. Currently, no approved therapies exist for the prevention of relapse in MOGAD, and in about 80% of adult patients, the disease is chronic and characterized by a relapsing course with currently used therapies. The inflammatory cytokine IL-6 may play a role in the pathogenesis of MOGAD by promoting the production of autoantibodies and inducing inflammatory effects. The number of patients in Japan is estimated to be approximately 1,700.お知らせ • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.お知らせ • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.お知らせ • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026お知らせ • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.最新情報をもっと見るRecent updatesお知らせ • 2hChugai Pharmaceutical Files For Additional Indication Of Enspryng For Prevention Of Relapse In MOG Antibody-Associated Disease In JapanChugai Pharmaceutical Co., Ltd. filed a regulatory application with the Ministry of Health, Labour and Welfare for an additional indication of 'prevention of relapse in MOG antibody-associated disease' for Enspryng [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. Enspryng received forerunner designation in 2023 as a treatment for the disease. If approved, Enspryng would become the first treatment covered by health insurance in Japan for the disease. This filing is based on results from METEOROID, a global phase III clinical study in adults and adolescents (aged 12-17 years) with MOGAD. Development in Japan is conducted by Chugai, and Japanese patients have participated in this study. Enspryng, created by Chugai, is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, which was the first product developed by applying Chugai's proprietary recycling antibody technology. Recycling antibody technology received 'The Imperial Invention Prize,' the highest honor of the Fiscal Year 2026 National Commendation for Invention. Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in approximately 90 countries, including Japan, the United States, and Europe. A global phase III clinical study is currently ongoing in autoimmune encephalitis (AIE). In addition, the U.S. Food and Drug Administration (FDA) has accepted the filing for thyroid eye disease (TED) and granted priority review. MOG antibody-associated disease (myelin oligodendrocyte glycoprotein antibody-associated disease, MOGAD) is an autoimmune disease involving demyelination by which a pathogenic autoantibody, an anti-MOG antibody, binds to MOG, which is expressed on the surface of the myelin sheath in the central nervous system. MOGAD causes inflammation of the optic nerves, spinal cord and brain, with symptoms such as visual impairment, loss of sensation, motor dysfunction and dysuria. Currently, no approved therapies exist for the prevention of relapse in MOGAD, and in about 80% of adult patients, the disease is chronic and characterized by a relapsing course with currently used therapies. The inflammatory cytokine IL-6 may play a role in the pathogenesis of MOGAD by promoting the production of autoantibodies and inducing inflammatory effects. The number of patients in Japan is estimated to be approximately 1,700.お知らせ • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.お知らせ • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.お知らせ • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026お知らせ • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.お知らせ • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Guidance for the Financial Year Ending December 31, 2025Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.お知らせ • Jan 31Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025.お知らせ • Jan 16CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519).CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.お知らせ • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025お知らせ • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.株主還元CUP0DE PharmaceuticalsDE 市場7D-3.8%3.5%3.0%1Y-14.4%45.4%1.8%株主還元を見る業界別リターン: CUP0過去 1 年間で45.4 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: CUP0は、過去 1 年間で1.8 % のリターンを上げたGerman市場を下回りました。価格変動Is CUP0's price volatile compared to industry and market?CUP0 volatilityCUP0 Average Weekly Movement6.6%Pharmaceuticals Industry Average Movement5.8%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: CUP0 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: CUP0の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19255,104Osamu Okudawww.chugai-pharm.co.jp中外製薬株式会社は、子会社とともに、国内外において医薬品の研究開発、製造、販売、輸入および輸出を行っています。アレセンサ、アバスチン、ファンデーションワン、ハーセプチン、カドサイラ、ペルジェタ、ポリビ、テセントリク、フェスゴなどのがん領域製品、ヒト化抗ヒトIL-6レセプターモノクローナル抗体「アクテムラ」、免疫抑制剤「セルセプト」、骨粗鬆症治療剤「エディロール」、pH依存性結合ヒト化抗IL-6レセプターモノクローナル抗体「エンスプリング」、脊髄性筋萎縮症治療剤「エブリスディ」などを提供しています；抗凝固因子IXa/Xヒト化二重特異性モノクローナル抗体Hemlibra、赤血球造血刺激因子製剤Mircera、pH依存性結合ヒト化抗補体（C5）モノクローナル抗体PiaSky、抗SARS-CoV-2モノクローナル抗体Ronapreve、抗インフルエンザウイルス剤Tamiflu、抗VEGF/抗Ang-2二重特異性抗体Vabysmo。同社はロシュ・グループと戦略的提携および共同研究を行っており、アラリス・バイオテックAGとはアラリスAraLinQ技術を用いたADC開発のための共同研究およびライセンスオプション契約を結んでいる。同社は1925年に設立され、日本の中央区に本社を置いている。中外製薬株式会社はロシュ・ホールディング・リミテッドの子会社です。もっと見るChugai Pharmaceutical Co., Ltd. 基礎のまとめChugai Pharmaceutical の収益と売上を時価総額と比較するとどうか。CUP0 基礎統計学時価総額€63.32b収益（TTM）€2.57b売上高(TTM)€7.31b24.7xPER（株価収益率8.7xP/SレシオCUP0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CUP0 損益計算書（TTM）収益JP¥1.34t売上原価JP¥384.81b売上総利益JP¥958.00bその他の費用JP¥486.63b収益JP¥471.37b直近の収益報告Jun 30, 2026次回決算日Oct 27, 2026一株当たり利益（EPS）286.50グロス・マージン71.34%純利益率35.10%有利子負債／自己資本比率0%CUP0 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.9%現在の配当利回り48%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/30 20:45終値2026/07/30 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Chugai Pharmaceutical Co., Ltd. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27 アナリスト機関Atsushi SekiBarclaysMiki SogiBernsteinKoichi MameganoBofA Global Research24 その他のアナリストを表示
お知らせ • 2hChugai Pharmaceutical Files For Additional Indication Of Enspryng For Prevention Of Relapse In MOG Antibody-Associated Disease In JapanChugai Pharmaceutical Co., Ltd. filed a regulatory application with the Ministry of Health, Labour and Welfare for an additional indication of 'prevention of relapse in MOG antibody-associated disease' for Enspryng [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. Enspryng received forerunner designation in 2023 as a treatment for the disease. If approved, Enspryng would become the first treatment covered by health insurance in Japan for the disease. This filing is based on results from METEOROID, a global phase III clinical study in adults and adolescents (aged 12-17 years) with MOGAD. Development in Japan is conducted by Chugai, and Japanese patients have participated in this study. Enspryng, created by Chugai, is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, which was the first product developed by applying Chugai's proprietary recycling antibody technology. Recycling antibody technology received 'The Imperial Invention Prize,' the highest honor of the Fiscal Year 2026 National Commendation for Invention. Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in approximately 90 countries, including Japan, the United States, and Europe. A global phase III clinical study is currently ongoing in autoimmune encephalitis (AIE). In addition, the U.S. Food and Drug Administration (FDA) has accepted the filing for thyroid eye disease (TED) and granted priority review. MOG antibody-associated disease (myelin oligodendrocyte glycoprotein antibody-associated disease, MOGAD) is an autoimmune disease involving demyelination by which a pathogenic autoantibody, an anti-MOG antibody, binds to MOG, which is expressed on the surface of the myelin sheath in the central nervous system. MOGAD causes inflammation of the optic nerves, spinal cord and brain, with symptoms such as visual impairment, loss of sensation, motor dysfunction and dysuria. Currently, no approved therapies exist for the prevention of relapse in MOGAD, and in about 80% of adult patients, the disease is chronic and characterized by a relapsing course with currently used therapies. The inflammatory cytokine IL-6 may play a role in the pathogenesis of MOGAD by promoting the production of autoantibodies and inducing inflammatory effects. The number of patients in Japan is estimated to be approximately 1,700.
お知らせ • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.
お知らせ • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.
お知らせ • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.
お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026
お知らせ • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.
お知らせ • 2hChugai Pharmaceutical Files For Additional Indication Of Enspryng For Prevention Of Relapse In MOG Antibody-Associated Disease In JapanChugai Pharmaceutical Co., Ltd. filed a regulatory application with the Ministry of Health, Labour and Welfare for an additional indication of 'prevention of relapse in MOG antibody-associated disease' for Enspryng [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. Enspryng received forerunner designation in 2023 as a treatment for the disease. If approved, Enspryng would become the first treatment covered by health insurance in Japan for the disease. This filing is based on results from METEOROID, a global phase III clinical study in adults and adolescents (aged 12-17 years) with MOGAD. Development in Japan is conducted by Chugai, and Japanese patients have participated in this study. Enspryng, created by Chugai, is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, which was the first product developed by applying Chugai's proprietary recycling antibody technology. Recycling antibody technology received 'The Imperial Invention Prize,' the highest honor of the Fiscal Year 2026 National Commendation for Invention. Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in approximately 90 countries, including Japan, the United States, and Europe. A global phase III clinical study is currently ongoing in autoimmune encephalitis (AIE). In addition, the U.S. Food and Drug Administration (FDA) has accepted the filing for thyroid eye disease (TED) and granted priority review. MOG antibody-associated disease (myelin oligodendrocyte glycoprotein antibody-associated disease, MOGAD) is an autoimmune disease involving demyelination by which a pathogenic autoantibody, an anti-MOG antibody, binds to MOG, which is expressed on the surface of the myelin sheath in the central nervous system. MOGAD causes inflammation of the optic nerves, spinal cord and brain, with symptoms such as visual impairment, loss of sensation, motor dysfunction and dysuria. Currently, no approved therapies exist for the prevention of relapse in MOGAD, and in about 80% of adult patients, the disease is chronic and characterized by a relapsing course with currently used therapies. The inflammatory cytokine IL-6 may play a role in the pathogenesis of MOGAD by promoting the production of autoantibodies and inducing inflammatory effects. The number of patients in Japan is estimated to be approximately 1,700.
お知らせ • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.
お知らせ • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.
お知らせ • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.
お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026
お知らせ • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.
お知らせ • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Guidance for the Financial Year Ending December 31, 2025Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.
お知らせ • Jan 31Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025.
お知らせ • Jan 16CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519).CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.
お知らせ • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025
お知らせ • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.
